9 protocol(s) meet the specified criteria
Drug: VP-16
Protocol No.TitleStatus
AC220-007A Phase 3 Open-Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory To or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplant (HSCT) ConsolidationOpen
CALGB10503Phase II Study of Maintenance Therapy with Decitabine (NSC #127716, IND #50733) Following Standard Induction and Cytogenetic Risk-Adapted Intensification in Previously Untreated Patients with AML < 60 YearsOpen (affiliates only)
CALGB30610Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin and EtoposideOpen (affiliates only)
CALGB50403A Randomized Phase II Trial of Maintenance vs Consolidation Bortezomib Therapy Following Aggresive Chemo-Immunotherapy and Autologous Stem Cell Transplant for Previously Untreated Mantle Cell LymphomaOpen (affiliates only)
COGAAML1031A Phase III Randomized Trial for Patients with de novo AML using Bortezomib(IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND#69896, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITDOpen
E1910A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults.Open
LCCC1503A Phase I/Ib Study of Alisertib plus R-EPOCH for Treatment of Myc-Positive Aggressive B-Cell LymphomasOpen
MSKCC-13-074Randomized phase II trial of paclitaxel, ifosfamide, and cisplatin (TIP) vs. bleomycin, etoposide and cisplatin (BEP) for patients with previously untreated intermediate- and poor- risk germ cell tumorsOpen
SGN19A-003A randomized, open-label phase 2 study of denintuzumab mafodotin (SGN-CD19A) plus rituximab, ifosfamide, carboplatin, and etoposide (19A+RICE) chemotherapy vs. RICE in the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are candidates for autologous stem cell transplantOpen